In8Bio (INAB) Construction in Progress (2021 - 2022)

In8Bio (INAB) posted Construction in Progress of $497000.0 for Q1 2022, up 23.33% sequentially from $403000.0 in Q4 2021.

In8Bio (INAB) Construction in Progress (2021 - 2022) Analysis & Trends

In8Bio has reported Construction in Progress for 2 years, with the latest figure at $497000.0 in Q1 2022.

Quarterly Construction in Progress changed N/A year-over-year to $497000.0 in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $497000.0 (changed N/A YoY) and the FY2021 annual result came in at $403000.0, changed N/A from the prior year.
Construction in Progress climbed to $497000.0 in Q1 2022 per INAB's latest filing, from $403000.0 in the prior quarter.
Over five years, Construction in Progress peaked at $497000.0 in Q1 2022 and troughed at $183000.0 in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Construction in Progress (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	152.67 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	In8Bio	24.34 Mn	24.34 Mn	-	-

Download Data